You are here

Best Available Treatment Study for the Paediatric Inflammatory Multisystem Inflammatory Syndrome

COVID-19 Research Area(s): Vaccines & Treatments

There are reports from throughout the world of children presenting with fever and other signs of inflammation in the setting of the COVID-19 pandemic. This newly identified syndrome is referred to as multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19.
 
While randomized trials are needed to determine optimal MIS-C treatment, they will take time to establish. The proposed "best available treatment study" is an international initiative aimed at rapidly evaluating the current treatments being employed by clinicians to treat patients with MIS-C. The aims are: determine which patients to treat, which treatments work, and which may be harmful.